Edition:
India

Abcam PLC (ABCA.L)

ABCA.L on London Stock Exchange

1,441.00GBp
23 Oct 2020
Change (% chg)

16.00 (+1.12%)
Prev Close
1,425.00
Open
1,442.00
Day's High
1,489.00
Day's Low
1,400.00
Volume
1,598,949
Avg. Vol
470,901
52-wk High
1,584.00
52-wk Low
943.00

Summary

Name Age Since Current Position

Peter Allen

2018 Non-Executive Chairman of the Board

Alan Hirzel

2014 Chief Executive Officer, Executive Director

Michael Baldock

56 2020 Chief Financial Officer

Marc Perkins

2019 Associate General Counsel and Interim Company Secretary

Mara Aspinall

57 2018 Non-Executive Independent Director

Susan Harris

55 2014 Non-Executive Independent Director

Giles Kerr

60 2018 Non-Executive Independent Director

Louise Patten

64 2018 Senior Independent Non-Executive Director

James Staveley

2019 Vice President - Investor Relations

Biographies

Name Description

Peter Allen

Mr. Peter Vance Allen is Non-Executive Chairman of the Board of the Company. Mr. Peter has over 20 years’ experience as an executive director, non-executive director and chairman in a wide range of life science companies playing a significant role in their growth. He spent three years as Chairman of Proximagen Neurosciences plc (2009–2012), six years at ProStaken Group plc as Chairman (2007– 2013) and interim CEO (2010–2011), and 12 years at Celltech Group plc (1992–2004) as CFO and Deputy CEO. Peter is currently Non-Executive Chairman of AIM-listed Advanced Medical Solutions plc, Clinigen plc and Diurnal plc and privatelyowned Oxford Nanopore Technologies Ltd. He is a Non- Executive Director of Istesso Ltd. A chartered accountant by background, Peter brings to Abcam his experience as a chairman and board member and has substantial experience in M&A, international growth, fundraising and investor relations, as well as the commercialization of intellectual property.

Alan Hirzel

Mr. Alan Thomas Hirzel is Chief Executive Officer, Executive Director of Abcam Plc. Mr. Alan joined the business in 2013 following a strategic review which he led with the Founder and Board to define a long-term growth plan for Abcam. He has subsequently led the Company to achieve over 100% growth, and through substantial organisation change. Prior to joining Abcam, Alan was a Partner at Bain & Company where he advised global executives and private equity investors on growth strategy, performance improvement and acquisitions. Early in his career he worked in a variety of roles from life science researcher at Cornell University to new product development research at Kraft Foods. He holds BS, MS and MBA degrees from Cornell University. He also has a passion for social enterprise and was involved in establishing two social venture philanthropy organisations in the UK and later acted as a Trustee for the National Citizen’s Service Trust.

Michael Baldock

Mr. Michael Shaun Baldock has been appointed as Chief Financial Officer of the Company effective 2/3/2020. Michael Shaun Baldock has been appointed as Chief Financial Officer of the Company effective 2/3/2020. Michael has over 30 years of relevant functional and sector experience acquired through senior leadership roles at HSBC, Lazard, Bentley Health Care and SG Warburg. He is a founding partner at Ondra Partners, an independent financial advisory firm which has advised Abcam for several years. The Board believe that his experience, deep sector expertise and knowledge of Abcam make him an ideal candidate to lead Abcam's financial and strategic growth plans.

Marc Perkins

Mr. Marc Perkins is the Associate General Counsel and Interim Company Secretary of the Company.

Mara Aspinall

Ms. Mara Glickman Aspinall is Non-Executive Independent Director of the Company. Ms. Mara is Managing Director of BlueStone Venture Partners and CEO of Health Catalysts Group. Previously, Mara was President and CEO of Ventana Medical Systems/Roche Tissue Diagnostics, leading the company to increased market leadership worldwide and primacy in companion diagnostics. Mara spent 12 years at Genzyme Corporation (now part of Sanofi) as President of Genzyme Genetics and Genzyme Pharmaceuticals. She is co-founder of the International School of Biomedical Diagnostics at Arizona State University, the only institution dedicated to the study of diagnostics as an independent discipline. She is a Fellow of the American Institute for Medical and Biological Engineering. Ms. Mara is a Director of Allscripts Healthcare Solutions Inc, Castle Biosciences, Blue Cross Blue Shield Arizona, OraSure Technologies, Strateos (was 3Scan Inc), RainBird and Paradigm Diagnostics.

Susan Harris

Ms. Susan Elizabeth (Sue) Harris is Non-Executive Independent Director of the Company. A chemist by training, Sue has held senior executive positions in retail and financial services. She held senior roles at Marks & Spencer plc across finance and strategy, latterly as Head of Corporate Development and Group Treasurer. She was Managing Director Finance at Standard Life, where she led the process to float the group. She was Finance Director of Cheltenham & Gloucester, Lloyds Banking Group’s Retail Bank and Group Finance and Group Audit Director. Sue has several years’ experience as a non-executive director. Previously she was a Non- Executive Director of St. James’s Place and Bank of Ireland UK, Chair of Trustees for KCP Youth and chaired the finance and audit committees of Mencap. Sue is a Non-Executive Director of Schroder & Co Limited, FNZ, Barclays Pension Funds Trustees Limited and Co-operative Bank, and is Chair of the Audit and Assurance Council and a member of the Codes and Standards Committee of the Financial Reporting Council.

Giles Kerr

Mr. Giles Francis Bertram Kerr is Non-Executive Independent Director of the Company. Mr. Giles has substantial commercial and financial experience from service on numerous public and private company boards and as an audit partner. From 1990 he served in a variety of increasingly senior roles at Amersham plc, including as Chief Financial Officer and a Board member from 1997 to 2004, when the company was acquired by GE Healthcare. Prior to his roles at Amersham, he was a National Partner with Arthur Andersen. He was Director of Finance of the University of Oxford from 2005 until 2018 and was previously a Director of Victrex plc, BTG plc, and Elan Corporation Inc. Giles is currently a Non-Executive Director of Arix Bioscience plc, Adaptimmune Therapeutics plc, PayPoint plc, Senior plc and Oxford Sciences Innovation plc.

Louise Patten

Ms. Louise A. V. C. Patten is Senior Independent Non-Executive Director of the Company. Ms. Patten is Having started her career in corporate and investment banking, Louise moved into management consultancy and became a Board Director of the Hilton Group. Since then she has served on a succession of multi-national listed company boards for more than 20 years as a non-executive director, a senior independent director, a remuneration committee chairman and a company chairman at organisations including the retailers Marks & Spencer plc, GUS plc and Somerfield plc. Louise is currently a Senior Advisor to Bain & Company and a Non-Executive Director of Arthur J. Gallagher (UK) Limited, Arthur J. Gallagher Holdings (UK) Limited and Arthur J Gallagher Insurance Brokers Limited. Louise’s highly recognised career in business, with her extensive board and corporate governance experience, brings Abcam the knowledge and proficiency required to support its strategic growth plans and, whilst doing this, ensures that the Abcam Board is led by a robust governance framework.

James Staveley

Basic Compensation

Name Fiscal Year Total

Peter Allen

225,000

Alan Hirzel

1,914,000

Michael Baldock

--

Marc Perkins

--

Mara Aspinall

71,000

Susan Harris

83,000

Giles Kerr

39,000

Louise Patten

83,000

James Staveley

--
As Of  30 Jun 2019